Larvol Delta - ASLAN-Pharmaceuticals-Announces-Acceptance-of-Late-Breaker-Abstract-on-Eblasakimab-Phase-2b-Results-as-Oral-Presentation-and-Three-Additional-Abstracts-at-32nd-European-Academy-of-Dermatology-and-Venereology-Congress

eblasakimab (ASLAN004) - ASLAN Pharma, Zenyaku Holdings

https://www.globenewswire.com/news-release/2023/09/22/2747884/0/en/ASLAN-Pharmaceuticals-Announces-Acceptance-of-Late-Breaker-Abstract-on-Eblasakimab-Phase-2b-Results-as-Oral-Presentation-and-Three-Additional-Abstracts-at-32nd-European-Academy-of-.html

Sep 22, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next